Beyond the Blue Petal: Unravelling the Dual Pharmacological Power of Clitoria ternatea

Figure 1. Schematic representation of the core chromophore of ternatin anthocyanins from Clitoria ternatea, showing the flavylium cation ring system (A, B, C rings), key hydroxyl substituents on the B-ring (3′,4′,5′-OH; pyrogallol configuration), glucosyl attachment at position 3 (with malonyl group), and 3′ and 5′ positions (acylated with p-coumaroyl-glucose chains to form individual ternatins). Original schematic, drawn for this revie

Figure 2. Proposed biosynthetic pathway of ternatin anthocyanins in Clitoria ternatea flower petals, based on enzymatic characterisation by Kogawa et al. (2007) and Vidana Gamage et al. (2021) [5]. CHS = chalcone synthase; CHI = chalcone isomerase; F3H = flavanone 3-hydroxylase; F3′5′H = flavonoid 3′,5′-hydroxylase; ANS = anthocyanidin synthase; Ct3GT-A = UDP-glucose:anthocyanidin 3-O-glucosyltransferase; UGAT = UDP-glucose:anthocyanin glucosyltransferase; AAT = anthocyanin acyltransferase. Original schematic, drawn for this review.

3.2 Flavonol Glycosides

Alongside anthocyanins, the flowers and leaves contain flavonol glycosides — principally quercetin-3-O-beta-glucoside, kaempferol-3-O-beta-glucoside, and myricetin-3-O-beta-glucoside ^[5]. These compounds possess well-documented, mechanistically distinct anti-inflammatory activities, including direct NF-kB signalling inhibition, COX-2 and iNOS transcriptional suppression, and LOX pathway modulation ^[8]. Crucially, quercetin-3-O-beta-glucoside from C. ternatea petals has specifically been demonstrated to inhibit TNFR1-mediated signalling and downregulate synovial matrix metalloprotease expression, providing a molecular correlate of anti-rheumatoid activity ^[8].

3.3 Phenolic Acids

Seed oils of C. ternatea contain an abundant and analytically characterised phenolic acid fraction, dominated by sinapic acid and quercetin (total phenolic content 55-63 mg/100 g; quercetin content 67-116 mg/100 g) ^[3]. Sinapic acid contributes to both lipid peroxidation inhibition and, through hydrogen bonding with protein surface residues, protein conformational stabilisation under denaturing conditions. These compounds represent the primary pharmacological constituents of the seed oil preparations studied for protein denaturation inhibition ^[3].

3.4 Other Secondary Metabolites

Beyond the polyphenolic fraction, C. ternatea elaborates: (i) alkaloids — clitorine and trifolirhizin — in roots and seeds with documented neuroprotective and anti-inflammatory activities; (ii) cyclotides — ultra-stable cyclic peptide microproteins of the Cliotide family found in all plant tissues, with potent insecticidal activity mediated by membrane disruption; (iii) triterpenoid saponins in roots and seeds; (iv) condensed tannins in seed coats; and (v) sterols (beta-sitosterol, stigmasterol) in seed oils ^[14]. The cyclotides, while not directly relevant to oxidative stress or protein denaturation pharmacology, represent a unique research frontier for C. ternatea and underscore the structural diversity of its secondary metabolome.

TABLE 1. COMPREHENSIVE BIOACTIVE COMPOUND PROFILE OF CLITORIA TERNATEA

Table 1. Major classes of bioactive secondary metabolites in Clitoria ternatea, key individual constituents, primary plant parts, and pharmacological roles. Data compiled from Kazuma et al. [5,6,7], Vidana Gamage et al. [5], Nair et al. [8], Padmanabhan & Parvatam [3], and Al-Snafi [14].

4. Oxidative Stress Modulation: Evidence and Mechanistic Analysis

4.1 Chemical Radical Scavenging Assays (DPPH, FRAP, ABTS)

The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay is the foundational antioxidant test employed across all C. ternatea studies. The assay measures the capacity of a compound or extract to donate a hydrogen atom or electron to the stable DPPH radical, converting it to the colourless hydrazine form, measured spectrophotometrically at 517 nm. The quantitative data across studies are summarised below:

• Aqueous flower extract: IC50 = 0.47 ± 0.01 mg/mL — reflecting high polyphenol density and efficient HAT/SET mechanisms ^[1]
• Isolated anthocyanin-rich fraction: IC50 = 0.86 ± 0.07 mg/mL — lower potency than crude extract, confirming role of polyphenol synergism ^[4]
• Methanolic leaf extract: 62.39% scavenging at 150 µg/mL; methanolic flower extract: 44.08% at same concentration ^[9]
• Ethyl acetate flower extract (Vietnam study, 2025): IC50 = 474.76 µg/mL; methanolic leaf extract IC50 = 284.91 µg/mL ^[11]

Notably, the methanolic leaf extract consistently outperformed the flower extract in this Vietnamese comparative study ^[11], suggesting meaningful pharmacological diversity across plant parts — a finding that underscores the current bias toward flower-focused research and supports multi-part investigations.

The Ferric Reducing Antioxidant Power (FRAP) assay, quantifying the ability to reduce Fe3+ to Fe2+, yielded 0.38 mmol FeSO4 eq./mg dried aqueous flower extract ^[1]. The ABTS/TEAC assay produced a value of 0.17 mg Trolox equivalents/mg dried extract from the same preparation ^[1]. Together, these multiple-assay data validate the antioxidant potency through complementary mechanistic pathways: HAT (DPPH), SET (ABTS), and electron donation (FRAP).

4.2 Cellular Antioxidant Activity in Macrophage Models

The cellular antioxidant assay (CAA) using RAW264.7 murine macrophages provides pharmacologically superior evidence to chemical assays, as it incorporates cellular uptake, membrane permeability, and intracellular metabolic transformation of phytochemicals. AAPH (2,2′-azobis(2-methylpropionamidine) dihydrochloride) was used to generate peroxyl radicals intracellularly, with oxidation of DCFH-DA to fluorescent DCF as the readout ^[4].

At a concentration of 156.3 µg/mL, crude C. ternatea flower extract achieved 75-80% inhibition of intracellular ROS, while the isolated anthocyanin-rich fraction achieved only approximately 20% inhibition at the same concentration ^[4]. This four-fold disparity between crude extract and isolated fraction is a pharmacologically significant finding. It conclusively demonstrates that ternatin anthocyanins alone do not account for the cellular antioxidant activity and implicates co-operative interaction between ternatins, flavonol glycosides, and phenolic acids in producing maximal intracellular protection.

NOVEL INTERPRETATION: The divergence between chemical assay IC50 values (where isolated fractions perform relatively comparably to crude extracts) and cellular assay data (where crude extracts markedly outperform fractions) identifies two pharmacologically distinct phenomena: (1) direct radical quenching capacity — primarily attributed to ternatins; and (2) cellular antioxidant capacity — a synergistic whole-extract property not reducible to individual compounds. This distinction has direct implications for standardisation approaches in nutraceutical development.

4.3 Anti-Glycation and Oxidative Protein Modification Inhibition

Advanced glycation end products (AGEs) form through non-enzymatic Maillard-type reactions between reducing sugars or reactive carbonyl species and protein amino groups. Their accumulation in diabetic vasculature, neural tissue, and renal glomeruli drives the progression of diabetic complications through ROS generation, receptor-mediated inflammation (RAGE activation), and protein cross-linking. Inhibiting AGE formation therefore represents a dual antioxidant-anti-inflammatory pharmacological target ^[1].

Chayaratanasin et al. (2015) demonstrated that CTE at 0.25-1.00 mg/mL produced dose-dependent inhibition of fluorescent AGE formation in a BSA/fructose incubation system, alongside inhibition of beta-amyloid-like fibril formation and protein oxidation ^[1]. This represented the first evidence of C. ternatea anti-glycation activity, establishing its relevance to diabetes pharmacology beyond simple antioxidant testing.

Subsequent work by Gonon-Watthanasiri et al. (2021) extended this to a methylglyoxal (MG)/BSA model — more clinically representative than the fructose model because MG is a major endogenous dicarbonyl produced during glycolysis and lipid peroxidation ^[2]. At 0.25-1 mg/mL, CTE significantly inhibited MG-induced fluorescent AGE formation, reduced protein carbonyl content by 22% (at 1 mg/mL), and prevented 56% of MG-induced protein thiol depletion ^[2]. Additionally, CTE at 0.125-1 mg/mL prevented oxidative DNA strand cleavage in MG/lysine and AAPH-induced systems, correlating with inhibition of superoxide anion and hydroxyl radical generation ^[2]. The direct MG-trapping ability of CTE was quantified by HPLC, ranging from 15-43% dose-dependently ^[2].

4.4 Molecular Mechanisms of Antioxidant Action

The following antioxidant mechanisms are supported by the combined structural and experimental evidence:

• Hydrogen Atom Transfer (HAT): The catechol (3′,4′-diOH) and pyrogallol (3′,4′,5′-triOH) moieties of flavonoids donate hydrogen atoms to stabilise radical species. Bond dissociation enthalpy (BDE) calculations confirm that the 4′-OH of quercetin and the 3′-OH of delphinidin are thermodynamically preferred HAT sites ^[8]
• Single Electron Transfer (SET): The extended pi-conjugation of the flavylium cation in ternatins facilitates single electron donation to cationic radicals (DPPH+, ABTS+•), measured in SET-based ABTS and FRAP assays ^[4]
• Transition Metal Chelation: Ortho-dihydroxy groups in flavonols form stable 1:2 metal-ligand complexes with Fe2+ and Cu2+, sequestering catalytic metals that would otherwise generate hydroxyl radicals via Fenton and Haber-Weiss reactions ^[8]
• Carbonyl Trapping: Polyphenols directly react with reactive alpha-dicarbonyl species (methylglyoxal, glyoxal) through nucleophilic addition to carbonyl groups, forming stable adducts. This prevents protein and DNA glycation at its initiating step ^[1,2]
• Nrf2/ARE Pathway Modulation: Structurally analogous polyphenols (quercetin, kaempferol) are established inducers of the Nrf2-Keap1 antioxidant response pathway, upregulating endogenous cytoprotective enzymes (HO-1, NQO1, SOD, CAT, GPx). Direct experimental evidence for this mechanism specifically in C. ternatea remains to be generated and constitutes a priority research gap ^[9]

5. Protein Denaturation Inhibition: Evidence and Mechanisms

5.1 Theoretical and Assay Framework

Protein denaturation refers to the disruption of non-covalent interactions (hydrogen bonds, hydrophobic interactions, electrostatic forces) maintaining a protein's functional three-dimensional conformation. In the context of inflammation, auto-antigens generated from denatured proteins — including heat shock proteins, denatured collagen, and immunoglobulins — trigger innate and adaptive immune responses. This is particularly relevant to rheumatoid arthritis pathogenesis, where auto-antibody formation against denatured IgG (rheumatoid factor) and collagen are cardinal features ^[15].

The BSA (bovine serum albumin) heat denaturation assay, standardised by Mizushima and Kobayashi, measures turbidity at 660 nm following incubation of BSA at 70-72°C in the presence and absence of test extract. The percentage inhibition of denaturation reflects a compound's ability to stabilise protein conformation under thermal stress, and the method is validated against standard NSAIDs (diclofenac sodium, aspirin, ibuprofen) as reference compounds ^[10,13,15]. Its advantages include simplicity, reproducibility, low cost, and pharmacological relevance to anti-inflammatory screening.

5.2 Quantitative Evidence Across Plant Parts and Extract Types

The evidence base for C. ternatea protein denaturation inhibition has expanded considerably since 2015, now encompassing seed oils, flower petals, leaves, and roots:

• Ethanolic extracts of flowers and leaves demonstrated effective in vitro inhibition of heat-induced albumin denaturation, with the assay performed against 1% aqueous BSA at pH 6.5, incubated at 37°C for 20 min followed by 57°C for 30 min, with aspirin as reference standard ^[10]
• Methanolic leaf extract (Vietnamese study, 2025) produced the strongest protective effect against albumin denaturation with IC50 = 120.05 µg/mL, comparable to the diclofenac reference. The methanolic flower extract was also active in the same system ^[11]
• Blue-flowered (BSO) and white-flowered (WSO) seed oils both showed statistically significant in vitro protein denaturation inhibition attributed to their high sinapic acid and quercetin content, with no significant difference between varieties despite differing anthocyanin profiles ^[3]
• Aqueous root extract assessed for anti-arthritic potential via albumin denaturation inhibition — representing the first documented pharmacological rationale for traditional anti-arthritic use of C. ternatea root preparations ^[15]

Across studies, percentage inhibition values at test concentrations of 0.5-1.0 mg/mL range from 60 to 85%, pharmacologically comparable to reference NSAIDs in the same assay systems ^[10,11,13]. However, rigorously validated, full dose-response IC50 determinations with formal positive controls are inconsistently reported, representing a methodological limitation that warrants standardisation across future studies.

5.3 Mechanistic Basis of Protein Stabilisation

Several convergent molecular mechanisms underpin the protein denaturation inhibitory activity of C. ternatea phytochemicals:

• Hydrogen Bond Network Formation: Polyphenolic -OH groups of ternatins and flavonols form multiple hydrogen bonds with polar residues on the BSA surface (particularly Lys, Arg, Tyr, Ser side chains), increasing the energy barrier for unfolding and effectively acting as molecular chaperones ^[3,8]
• Hydrophobic Groove Intercalation: The aromatic rings of ternatin anthocyanins and quercetin intercalate within the hydrophobic pockets of BSA (Sudlow Sites I and II), increasing thermodynamic stability of the native conformation and raising the melting temperature (Tm) of the protein ^[8]
• NF-kB Pathway Suppression: Quercetin-3-O-beta-glucoside from C. ternatea petals directly inhibits TNFR1-mediated NF-kB activation, reducing downstream transcription of COX-2, iNOS, and pro-inflammatory cytokines (IL-6, TNF-alpha) that amplify the inflammatory protein damage cascade ^[8]
• ROS-Mediated Denaturation Prevention: By scavenging superoxide and hydroxyl radicals (documented in the MG/lysine model), CTE prevents oxidative modifications — principally carbonylation and disulfide bond formation — that initiate denaturation in oxidative conditions, mechanistically bridging antioxidant and anti-denaturation activities ^[2,4]

6. Consolidated In Vitro Evidence

Table 2. Comprehensive Summary of In Vitro Pharmacological Data for Clitoria ternatea

TABLE 2. QUANTITATIVE SUMMARY OF IN VITRO ANTIOXIDANT AND PROTEIN DENATURATION INHIBITION DATA. CTE = Clitoria ternatea extract; BSA = bovine serum albumin; MG = methylglyoxal; AGEs = advanced glycation end products; CAA = cellular antioxidant activity. References: [1] Chayaratanasin 2015; [2] Gonon-Watthanasiri 2021; [3] Padmanabhan 2025; [4] Jeyaraj 2022; [9] Islam 2023; [10] Sampath 2014; [11] Nguyen 2025; [13] Sowmya 2023; [15] Sethupathy 2022.

Figure 4. Visual summary of key quantitative in vitro antioxidant parameters of Clitoria ternatea aqueous/hydroethanolic flower extract across four validated assays. DPPH IC50 lower value indicates greater potency. CAA value represents percentage ROS inhibition at 156.3 µg/mL in RAW264.7 macrophages. Data from Chayaratanasin et al. (2015) [1] and Jeyaraj et al. (2022) [4]. Original figure, drawn for this review.

7. Integrated Discussion: A Dual-Mechanism Pharmacological Framework

The evidence synthesised in this review demonstrates that the antioxidant and protein denaturation inhibitory activities of C. ternatea are not independent pharmacological phenomena but are mechanistically interlinked through shared molecular pathways. The oxidative stress — protein damage interface provides the conceptual framework: ROS-mediated carbonylation and thiol oxidation of proteins initiates their conformational unfolding, while denatured proteins in turn activate macrophage NADPH oxidase and NF-kB signalling, further amplifying ROS production in a self-reinforcing cycle ^[2,4]. CTE is uniquely positioned to interrupt this cycle at multiple points: radical scavenging (breaking the oxidative trigger), carbonyl trapping (preventing protein glycation), and NF-kB inhibition (blocking the inflammatory amplification loop) ^[2,8].

The consistent superiority of crude extracts over isolated fractions in cellular antioxidant models ^[4] — and the mechanistic diversity of individual components (ternatins for radical scavenging; quercetin glycosides for NF-kB inhibition; phenolic acids for protein stabilisation; tannins for carbonyl trapping) — strongly argue against single-compound reductionist approaches in both research and product development. This constitutes a pharmacologically distinct argument for whole-extract standardisation as the appropriate strategy for nutraceutical formulation.

Comparative analysis across extraction solvents — a dimension only recently beginning to receive systematic attention — reveals that ethyl acetate flower extracts (IC50 474.76 µg/mL for DPPH) are less potent than aqueous preparations (IC50 0.47 mg/mL) in radical scavenging ^[1,11]; however, methanolic leaf extracts consistently outperform flower preparations in anti-denaturation assays ^[11]. This solvent and plant-part differential pharmacological profile is pharmacologically significant and practically important: it indicates that optimisation of extraction strategy — dependent on target pharmacological endpoint — is essential for product development and cannot be generalised across studies.

From a translational perspective, the safety profile of C. ternatea is well-documented. No adverse effects were observed in rodent models at doses up to 2,000 mg/kg, the plant has millennia-long food and medicinal use history, and no known drug interactions have been reported ^[14]. This safety context contrasts favourably with NSAIDs, for which gastrointestinal, cardiovascular, and renal adverse event profiles are well-established clinical concerns. The combined pharmacological profile — multi-mechanism antioxidant activity, protein denaturation inhibition comparable to reference drugs, and established safety — positions C. ternatea as a credible candidate for evidence-based natural product development.

8. Research Gaps and Future Directions

Table 3. Identified Research Gaps and Structured Future Research Agenda

TABLE 3. CRITICAL KNOWLEDGE GAPS in the pharmacological characterisation of Clitoria ternatea with respect to oxidative stress modulation and protein denaturation inhibition, with evidence-linked future research directions.